Core Insights - PacBio's Revio long-read sequencing system is being utilized by Novogene to enhance its new lab in Munich, Germany, aimed at serving the European scientific community [1][2] - The Revio system offers increased accuracy and throughput, enabling cost-effective in-depth genomic research across various fields including rare diseases, cancer, microbes, and agriculture [1][2] Company Overview - PacBio is a leading life science technology company focused on developing advanced sequencing solutions to address complex genetic problems, utilizing both HiFi long-read and SBB short-read sequencing technologies [4] - Novogene is a prominent provider of genomic services with significant sequencing capacity and expertise, operating globally with nearly 2,000 employees and a strong publication record [7] Strategic Developments - The new lab at the Innovation and Start-Up Center for Biotechnology in Munich will serve as a strategic hub for Novogene's European operations, complementing its existing global network [2] - Novogene anticipates high demand for the Revio system particularly in the rare disease and cancer research sectors, due to its ability to detect complex genomic features that other technologies may miss [2][3] Technological Advancements - The Revio system is expected to enhance the efficiency of genomic research by integrating more automation into its workflows, making long-read data more accessible to a broader customer base [2] - The collaboration between PacBio and Novogene aims to support advanced genomic applications that can improve human health and environmental sustainability [3]

The call will be webcast and may be accessed at PacBio's website at https://investor.pacificbiosciences.com/. If using the dial-in option, please join the call ten minutes before the start time using the appropriate number above and ask to join the "PacBio Q2 Earnings Call." Pacific Biosciences of California, Inc. (NASDAQ: PACB) is a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve genetically c ...

MENLO PARK, Calif., July 15, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its second quarter 2024 financial results on Wednesday, August 7, 2024, at 4:30 pm Eastern Time. Date: Wednesday, August 7, 2024, at 4:30 pm ET (1:30 pm PT) Listen live via internet or replay: https://investor.pacificbiosciences.com/ Toll-free: 1-888-349-0136 International: 1-412-317-0459 About PacBio PacBio products are provided for Research Use Only. Not fo ...

Pacific Biosciences of California (PACB) , popularly known as PacBio and Form Bio, a provider of advanced computational life sciences technology, recently collaborated and announced a range of new initiatives intended toward advancing and unifying the Adeno-associated virus (AAV) industry. The initiatives, including an AAV data dictionary, open-source tools and more, are being driven by a new AAV Working Group, jointly assembled by Form Bio and PacBio and composed of leading AAV experts across industry and ...

Pacific Biosciences of California (PACB) closed the latest trading day at $1.37, indicating a +0.74% change from the previous session's end. This move outpaced the S&P 500's daily loss of 0.41%. Elsewhere, the Dow saw a downswing of 0.12%, while the tech-heavy Nasdaq depreciated by 0.71%. Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate ...

Consortium Delivers Publicly Available Datasets that Enrich Detection of Rare and Novel Genetic Variants for Advances in Human Disease Research "Joining forces with PacBio has enabled us to leverage their HiFi sequencing capabilities, enhancing the depth and accuracy of the genomic data we can offer to the research community," said Michael Schatz, Bloomberg Distinguished Professor at Johns Hopkins University. "This effort complements existing databases such as gnomAD, as long reads enable much greater sensi ...

Core Viewpoint - Pacific Biosciences of California, Inc. (PacBio) is experiencing growth driven by its focus on research and development, with optimism stemming from a solid first-quarter 2024 performance and ongoing product development activities, despite facing competition and macroeconomic challenges [1][3][10]. Company Performance - Year-to-date, PacBio's stock has declined by 80.9%, contrasting with a 6.9% growth in the industry and an 11.6% gain in the S&P 500 Composite [2]. - The company has a market capitalization of $509 million and projects an 18% growth for 2024, with earnings surpassing the Zacks Consensus Estimate in three of the last four quarters, averaging a surprise of 11.6% [3][10]. Research and Development Focus - PacBio is committed to enhancing its R&D efforts, focusing on developing new and existing platforms while increasing throughput and reducing costs for customers [4]. - The company is developing a high-throughput short-read platform expected to serve high-throughput labs, with an addressable market estimated at over $1 billion annually [6]. - Ongoing development of the next-generation SMRT cell aims to support a new high-throughput long-read platform, significantly increasing throughput compared to the Revio system [7]. Product Development Activities - PacBio is expanding its presence in the RNA-sequencing market, recently launching the PureTarget repeat expansion panel to examine genes linked to severe neurological conditions [8]. - The company introduced two high-throughput library preparation kits optimized for its Revio sequencing system and a versatile Nanobind DNA extraction kit, broadening the range of sample types for long-read sequencing [9]. Financial Results - In the first quarter of 2024, PacBio's earnings aligned with the Zacks Consensus Estimate, while revenues exceeded expectations, with notable growth in product and consumables revenues [10]. - Strong geographical performance in the Asia-Pacific region and EMEA contributed positively, alongside an expansion of the adjusted gross margin [10]. Market Challenges - Macroeconomic factors, including rising inflation and global supply-chain constraints, have negatively impacted PacBio's customers and extended sales cycles, potentially affecting revenues and operations throughout 2024 [11]. - The company faces stiff competition in the nucleic acid sequencing market, with competitors having more resources to adapt to new opportunities and technologies [12]. Estimate Trends - PacBio has seen a positive revision trend for 2024 estimates, with the Zacks Consensus Estimate for adjusted loss per share narrowing from $1.01 to $0.91 over the past 60 days [13]. - The estimated fiscal 2024 revenues are projected at $176.3 million, reflecting a 12.1% decrease from the previous year [13].

Pacific Biosciences of California (PACB) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future. Earnings Estimate Revisions Here at Zacks, we prioritize appraising the change in the projection of a company's future earnings over anything else. That's because we believe the present value of its future stream of earnings is what determines the fair value for its stock. We ...

Core Insights - The GREGoR Consortium has selected Ambry Genetics and PacBio to support the Pediatric Mendelian Genomics Research Center program aimed at understanding rare diseases [1][2] - The initiative will utilize long-read sequencing technology to analyze up to 7,000 human whole genomes over three years, focusing on rare disease etiology [2][3] Company Overview - Ambry Genetics is a leader in clinical genomic testing, translating scientific research into actionable test results and has a strong track record in genetic disease understanding [5] - PacBio specializes in advanced sequencing solutions, focusing on accuracy and quality through its HiFi long-read and SBB short-read sequencing technologies [6] Research Objectives - The collaboration aims to enhance understanding of rare diseases by incorporating innovative methods such as phenotyping, variant identification, and functional analysis of genetic alterations [3][4] - The project seeks to discover new rare variants and understand the role of epigenomics in disease manifestation, potentially revolutionizing diagnostic capabilities [3][4]

Pacific Biosciences of California, Inc. (PACB) , popularly known as PacBio, delivered an adjusted loss per share of 26 cents in first-quarter 2024, narrower than the year-ago loss of 31 cents per share. The adjusted loss per share aligned with the Zacks Consensus Estimate.The company’s GAAP loss per share was 29 cents in the quarter, narrower than the year-ago period’s loss of 36 cents.Revenues in DetailPacBio registered revenues of $38.8 million in the first quarter, down 0.2% year over year. The figure be ...